Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06875960 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

StatusRecruiting
PhasePhase 4
Started2026-02-24
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 13 months later Dec 1, 2026 → Jan 31, 2028
See other at-risk trials from Bristol-Myers Squibb

Amendment history

2026-09-04
Study Status, Oversight v5
Primary completion pushed: 2026-12-01 → 2028-01-31
Completion pushed: 2026-12-01 → 2028-01-31
2026-03-27
Study Status v4
Start dateestimated 2026-02-27→confirmed 2026-02-24
2026-02-19
Study Status, Contacts/Locations, IPDSharing v3
Start date2025-08-29→2026-02-27
Study sites3→4
2025-08-26
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sites3 entries, revised
LocalNew InstitutionYork -University 0002School Of Medicine
2025-07-30
Study Status, References v1
Start date2025-03-17→2025-08-29
2025-03-12
Original filing
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Trial Details
NCT Number NCT06875960
Lead Sponsor Bristol-Myers Squibb
Conditions Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Enrollment 35 participants
Start Date 2026-02-24
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-09